Primary T-cell lymphoma of muscle in a patient infected with human immunodeficiency virus.

G. Lum,T. Cosgriff,R. Byrne,V. Reddy

DOI: https://doi.org/10.1016/0002-9343(93)90341-L

1993-11-01

Abstract:

What problem does this paper attempt to address?

Clinical outcomes in children living with HIV treated for non-severe tuberculosis in the SHINE Trial

Chishala Chabala,Eric Wobudeya,Marieke M van der Zalm,Monica Kapasa,Priyanka Raichur,Robert Mboizi,Megan Palmer,Aarti Kinikar,Syed Hissar,Veronica Mulenga,Vidya Mave,Philippa Musoke,Anneke C Hesseling,Helen McIlleron,Diana Gibb,Angela Crook,Anna Turkova,Louise Choo,Genevieve Wills,Margaret J Thomason,Jaqueline Teera,Ellen Owen-Powell,Kristen LeBeau,David Baptiste,Charlotte McGowan,Moira Spyer,Joyce Lungu,Kevin Zimba,Khozya Zyambo,Chalilwe Chungu,Chimuka Tembo,Sharon Kunda,Ellen Shingalili,Semy Zulu,Terence Chipoya,Habulembe Mwanakalanga,Elias Chambela,Jessy M Hankombo,Mox Malama Kalumbi,Daniel Chola,Stephen Malama,Winnie Nansamba,Mark Ssenyonga,Willy Ssengooba,Gerald Businge,Jessica Workman,Anne-Marie Demers,Simon Schaaf,Robert Gie,Elisabetta Walters,Warren Zimri,Graeme Hoddinott,Anneen van Deventer,Pierre Goussard,Julie Morrison,Aparna Nijampurkar,Sameer Khan,Bency Joseph,Perumal Kannabiran Bhavani,G Prathiksha,Dhanaraj Baskaran,N S Gomathi,V Mythily,Hemanth Kumar,Silambu Chelvi,L Sekar,Luke Hanna,K Ramesh,Hema Latha,S Bharathi,Parveen Banu,Dino Xavier,Manjith Kumar,K Guru,Sasi Kumar,A Kesavan,A Gunasundari,G Mangalambal,Valarmathi Nagarajan,Shakeela Shankar,R Selvi,S Vaishnavi,Krishna Yadav,R Supriya,Hema Giranab,A Seetha,Stella Mary,S Gopika,S Rohini,M Revathy,Sarath Balaji,S Elilarasi,J Ganesh,M A Aravind,Sylvia Mulambo,Hope Mwanyungwi,Dharati Tapse,Manasi Sane,Amina Abdullah,Sarah Nakalanzi,Cynthia Mukisa Williams,Paul Revill,James Love-Koh,Simon Walker,Janet Darbyshire,Polly Clayden,Peter Donald,Varinder Singh,Malgosia Grzemska,Soumya Swaminathan,Sabine Verkuijl,Annemieke Brands,Tim Peto,Alwyn Mwinga,Katherine Fielding,Stephen M Graham,Steven B Welch,James A Seddon,Elizabeth Whittaker,Suzanne Anderson,Louis Grandjean,SHINE trial team

DOI: https://doi.org/10.1093/cid/ciae193

IF: 20.999

2024-04-10

Clinical Infectious Diseases

Abstract:Children living with HIV(CLWH) are at high risk of tuberculosis(TB) and face poor outcomes, despite antiretroviral treatment(ART). We evaluated outcomes in CLWH and HIV-uninfected children treated for non-severe TB in the SHINE trial. SHINE was a randomized trial that enrolled children aged <16 years with smear-negative, non-severe TB who were randomized to receive 4 vs 6 months of TB treatment and followed for 72 weeks. We assessed TB relapse/recurrence, mortality, hospitalizations, grade ≥3 adverse events by HIV status, and HIV virological suppression in CLWH. Of 1204 enrolled, 127(11%) were CLWH, of similar age (median(IQR) 3.6(1.2, 10.3) vs. 3.5(1.5, 6.9)years, p= 0.07), but more underweight (WAZ; -2.3(-3.3, -0.8) vs -1.0(-1.8, -0.2), p<0.01) and anemic (hemoglobin 9.5(8.7, 10.9) vs 11.5(10.4, 12.3)g/dl, p<0.01) compared to HIV-uninfected children. 68(54%) CLWH were ART-naïve; baseline median CD4 count 719(241-1134) cells/mm 3 , CD4% 16(10-26)%). CLWH were more likely to be hospitalized (aOR=2.4(1.3-4.6)) and die (aHR(95%CI) 2.6(1.2,5.8)). HIV status, age <3 years (aHR 6.3(1.5,27.3)), malnutrition (aHR 6.2(2.4,15.9)) and hemoglobin <7g/dl(aHR 3.8(1.3,11.5) independently predicted mortality. Among children with available VL, 45% and 61% CLWH had VL<1000copies/ml at weeks 24 and 48, respectively. There was no difference in the effect of randomized treatment duration (4 vs 6 months) on TB treatment outcomes by HIV status (p for interaction=0.42). We found no evidence of a difference in TB outcomes between 4 and 6 months of treatment for CLWH treated for non-severe TB. Irrespective of TB treatment duration, CLWH had higher rates of mortality and hospitalization than HIV-uninfected counterparts. This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/clinical-outcomes-in-children-living-with-hiv-treated-for-non-severe-tuberculosis We compared outcomes between children with and without HIV treated for non-severe TB. Regardless of treatment duration (4 or 6 months), children with HIV had similar TB outcomes but had higher mortality and hospitalization rates than their HIV-uninfected counterparts.

immunology,infectious diseases,microbiology
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis

Lufina Tsirizani Galileya,Roeland E Wasmann,Chishala Chabala,Helena Rabie,Janice Lee,Irene Njahira Mukui,Anneke Hesseling,Heather Zar,Rob Aarnoutse,Anna Turkova,Diana Gibb,Mark F Cotton,Helen McIlleron,Paolo Denti

DOI: https://doi.org/10.1371/journal.pmed.1004303

2023-11-21

Abstract:Background: The current World Health Organization (WHO) pediatric tuberculosis dosing guidelines lead to suboptimal drug exposures. Identifying factors altering the exposure of these drugs in children is essential for dose optimization. Pediatric pharmacokinetic studies are usually small, leading to high variability and uncertainty in pharmacokinetic results between studies. We pooled data from large pharmacokinetic studies to identify key covariates influencing drug exposure to optimize tuberculosis dosing in children. Methods and findings: We used nonlinear mixed-effects modeling to characterize the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide, and investigated the association of human immunodeficiency virus (HIV), antiretroviral therapy (ART), drug formulation, age, and body size with their pharmacokinetics. Data from 387 children from South Africa, Zambia, Malawi, and India were available for analysis; 47% were female and 39% living with HIV (95% on ART). Median (range) age was 2.2 (0.2 to 15.0) years and weight 10.9 (3.2 to 59.3) kg. Body size (allometry) was used to scale clearance and volume of distribution of all 3 drugs. Age affected the bioavailability of rifampicin and isoniazid; at birth, children had 48.9% (95% confidence interval (CI) [36.0%, 61.8%]; p < 0.001) and 64.5% (95% CI [52.1%, 78.9%]; p < 0.001) of adult rifampicin and isoniazid bioavailability, respectively, and reached full adult bioavailability after 2 years of age for both drugs. Age also affected the clearance of all drugs (maturation), children reached 50% adult drug clearing capacity at around 3 months after birth and neared full maturation around 3 years of age. While HIV per se did not affect the pharmacokinetics of first-line tuberculosis drugs, rifampicin clearance was 22% lower (95% CI [13%, 28%]; p < 0.001) and pyrazinamide clearance was 49% higher (95% CI [39%, 57%]; p < 0.001) in children on lopinavir/ritonavir; isoniazid bioavailability was reduced by 39% (95% CI [32%, 45%]; p < 0.001) when simultaneously coadministered with lopinavir/ritonavir and was 37% lower (95% CI [22%, 52%]; p < 0.001) in children on efavirenz. Simulations of 2010 WHO-recommended pediatric tuberculosis doses revealed that, compared to adult values, rifampicin exposures are lower in most children, except those younger than 3 months, who experience relatively higher exposure for all drugs, due to immature clearance. Increasing the rifampicin doses in children older than 3 months by 75 mg for children weighing <25 kg and 150 mg for children weighing >25 kg could improve rifampicin exposures. Our analysis was limited by the differences in availability of covariates among the pooled studies. Conclusions: Children older than 3 months have lower rifampicin exposures than adults and increasing their dose by 75 or 150 mg could improve therapy. Altered exposures in children with HIV is most likely caused by concomitant ART and not HIV per se. The importance of the drug-drug interactions with lopinavir/ritonavir and efavirenz should be evaluated further and considered in future dosing guidance. Trial registration: ClinicalTrials.gov registration numbers; NCT02348177, NCT01637558, ISRCTN63579542.
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

Ruth L Goodall,Sarah K Meredith,Andrew J Nunn,Adamu Bayissa,Anuj K Bhatnagar,Gay Bronson,Chen-Yuan Chiang,Francesca Conradie,Meera Gurumurthy,Bruce Kirenga,Nana Kiria,Daniel Meressa,Ronelle Moodliar,Gopalan Narendran,Nosipho Ngubane,Mohammed Rassool,Karen Sanders,Rajesh Solanki,S Bertel Squire,Gabriela Torrea,Bazarragchaa Tsogt,Elena Tudor,Armand Van Deun,I D Rusen,Oyunchimeg Adilaa,Sofia Alexandru,Katharine Bellenger,Jaclyn Bennet,Deborah Bennet,Priyanka Bindroo,Ghanshyam Borisagar,Claire Cook,Doljinsuren Dalai,Andrew Davis,Bouke de Jong,Wendy Dodds,Lynette Duckworth,Nonhlanhla Gahima,Belay Gebreegziabher,Anne Goldfeld,Mahmud Hanifa,Gareth Hughes,Ivan Kimuli,Jan Komrska,Nino Lomtadze,Brendan Murphy,Thando Mwelase,Joanitah Nalunjogi,Leena Patel,Irina Pirlog,Ishmael Qawiy,Mary Rauchenberger,Leen Rigouts,Carol Roach,Laura Rosu,Ezio Santos-Filho,Thirumaran Senguttuvan,Million Sisay,Rathinam Sridhar,Vignes Srinivasulu,Mekonnen Teferi,Helen Teklu,Narangarav Tsegeen,Odette van Amsterdam,Lisa White,Johanna Whitney,Chuluunbaatar Zagd

DOI: https://doi.org/10.1016/s0140-6736(22)02078-5

IF: 202.731

2022-11-01

The Lancet

Abstract:BACKGROUND: The STREAM stage 1 trial showed that a 9-month regimen for the treatment of rifampicin-resistant tuberculosis was non-inferior to the 20-month 2011 WHO-recommended regimen. In STREAM stage 2, we aimed to compare two bedaquiline-containing regimens with the 9-month STREAM stage 1 regimen.METHODS: We did a randomised, phase 3, non-inferiority trial in 13 hospital clinics in seven countries, in individuals aged 15 years or older with rifampicin-resistant tuberculosis without fluoroquinolone or aminoglycoside resistance. Participants were randomly assigned 1:2:2:2 to the 2011 WHO regimen (terminated early), a 9-month control regimen, a 9-month oral regimen with bedaquiline (primary comparison), or a 6-month regimen with bedaquiline and 8 weeks of second-line injectable. Randomisations were stratified by site, HIV status, and CD4 count. Participants and clinicians were aware of treatment-group assignments, but laboratory staff were masked. The primary outcome was favourable status (negative cultures for Mycobacterium tuberculosis without a preceding unfavourable outcome) at 76 weeks; any death, bacteriological failure or recurrence, and major treatment change were considered unfavourable outcomes. All comparisons used groups of participants randomly assigned concurrently. For non-inferiority to be shown, the upper boundary of the 95% CI should be less than 10% in both modified intention-to-treat (mITT) and per-protocol analyses, with prespecified tests for superiority done if non-inferiority was shown. This trial is registered with ISRCTN, ISRCTN18148631.FINDINGS: Between March 28, 2016, and Jan 28, 2020, 1436 participants were screened and 588 were randomly assigned. Of 517 participants in the mITT population, 133 (71%) of 187 on the control regimen and 162 (83%) of 196 on the oral regimen had a favourable outcome: a difference of 11·0% (95% CI 2·9-19·0), adjusted for HIV status and randomisation protocol (p<0·0001 for non-inferiority). By 76 weeks, 108 (53%) of 202 participants on the control regimen and 106 (50%) of 211 allocated to the oral regimen had an adverse event of grade 3 or 4; five (2%) participants on the control regimen and seven (3%) on the oral regimen had died. Hearing loss (Brock grade 3 or 4) was more frequent in participants on the control regimen than in those on the oral regimen (18 [9%] vs four [2%], p=0·0015). Of 134 participants in the mITT population who were allocated to the 6-month regimen, 122 (91%) had a favourable outcome compared with 87 (69%) of 127 participants randomly assigned concurrently to the control regimen (adjusted difference 22·2%, 95% CI 13·1-31·2); six (4%) of 143 participants on the 6-month regimen had grade 3 or 4 hearing loss.INTERPRETATION: Both bedaquiline-containing regimens, a 9-month oral regimen and a 6-month regimen with 8 weeks of second-line injectable, had superior efficacy compared with a 9-month injectable-containing regimen, with fewer cases of hearing loss.FUNDING: USAID and Janssen Research & Development.

medicine, general & internal
Effectiveness of double-dose dolutegravir in people receiving rifampin-based tuberculosis treatment: an observational, cohort study of people with HIV from six countries

N Sarita Shah,Cissy Kityo,Michael D Hughes,Caitlyn McCarthy,Carole Wallis,Mina Hosseinipour,Deborah Langat,Mulinda Nyirenda,Mohammed Rassool,Rodney Dawson,Yvetot Joseph,Fatma Some,Rosie Mngqbisa,Pamela Grace Mukwekwerere,Elizabeth Woolley,Catherine Godfrey,Yukari C Manabe,John W Mellors,Charles Flexner,Gary Maartens,Vuyokazi S Jezile,Thando Mwelase,Marie Jude Jean Louis,Daphie Jean François,Abraham Siika,Viola Kirui,Penelope Madlala,Petronella Casey,Wadzanai Samaneka,Yeukai Musodza,Nadia Magengo,Suri Moonsamy,ACTG A5381/Hakim Study Team

DOI: https://doi.org/10.1093/cid/ciae269

IF: 20.999

2024-05-15

Clinical Infectious Diseases

Abstract:Tenofovir-lamivudine-dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen. An additional 50 mg dose of dolutegravir (TLD + 50) is required with rifampin-containing tuberculosis (TB) co-treatment. There are limited data on the effectiveness of TLD + 50 in individuals with TB/HIV. Prospective, observational cohort study at 12 sites in Haiti, Kenya, Malawi, South Africa, Uganda, Zimbabwe. Participants starting TLD and rifampin-containing TB treatment were eligible. Primary outcome was HIV-1 RNA ≤1000 copies/mL at end of TB treatment. We enrolled 91 participants with TB/HIV: 75 (82%) ART-naïve participants starting TLD after a median 15 days on TB treatment, 10 (11%) ART-naïve participants starting TLD and TB treatment, 5 (5%) starting TB treatment after a median 3.3 years on TLD, and 1 (1%) starting TB treatment and TLD after changing from efavirenz/lamivudine/tenofovir. Median age was 37 years, 35% female, median CD4 count 120 cells/mm 3 (IQR 50–295), 87% had HIV-1 RNA >1000 copies/mL. Two participants died during TB treatment. Among 89 surviving participants, 80 were followed to TB treatment completion, including 7 who had no HIV-1 RNA result due to missed visits. Primary virologic outcome was assessed in 73 participants, of whom 69 (95%, 95% CI 89–100%) had HIV-1 RNA ≤1000 copies/mL. No dolutegravir resistance mutations were detected among four participants with HIV-1 RNA >1000 copies/mL. In routine programmatic settings, concurrent rifampin-containing TB treatment and TLD + 50 was feasible, well-tolerated, and achieved high rates of viral suppression in a cohort of predominantly ART-naïve people with TB/HIV.

immunology,infectious diseases,microbiology
Treatment of schizophrenia and delusional disorder in the elderly

J. Eastham,D. Jeste

DOI: https://doi.org/10.1007/BF02900217

European Archives of Psychiatry and Clinical Neuroscience

Abstract:
Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV

Lufina Tsirizani,Shaghayegh Mohsenian Naghani,Hylke Waalewijn,Alexander Szubert,Veronica Mulenga,Chishala Chabala,Mutsa Bwakura-Dangarembizi,Moses Chitsamatanga,Diana A Rutebarika,Victor Musiime,Mariam Kasozi,Abbas Lugemwa,Lara N Monkiewicz,Helen M McIlleron,David M Burger,Diana M Gibb,Paolo Denti,Roeland E Wasmann,Angela Colbers

DOI: https://doi.org/10.1093/jac/dkae319

2024-11-04

Abstract:Background: Darunavir is a potent HIV protease inhibitor with a high barrier to resistance. We conducted a nested pharmacokinetic sub-study within CHAPAS-4 to evaluate darunavir exposure in African children with HIV, taking once-daily darunavir/ritonavir for second-line treatment. Methods: We used data from the CHAPAS-4 pharmacokinetic sub-study treating children with once-daily darunavir/ritonavir (600/100 mg if 14-24.9 kg and 800/100 mg if ≥25 kg) with either tenofovir alafenamide fumarate (TAF)/emtricitabine (FTC), abacavir/lamivudine or zidovudine/lamivudine. Steady-state pharmacokinetic sampling was done at 0, 1, 2, 4, 6, 8, 12 and 24 hours after observed darunavir/ritonavir intake. Non-compartmental and population pharmacokinetic analyses were used to describe the data and identify significant covariates. Reference adult pharmacokinetic data were used for comparison. We simulated the World Health Organization (WHO) recommended 600/100 mg darunavir/ritonavir dose for the 25-34.9 kg weight band. Results: Data from 59 children with median age and weight 10.9 (range 3.8-14.7) years and 26.0 (14.5-47.0) kg, respectively, were available. A two-compartment disposition model with transit absorption compartments and weight-based allometric scaling of clearance and volume best described darunavir data. Our population achieved geometric mean (%CV) darunavir AUC0-24h, 94.3(50) mg·h/L and Cmax, 9.1(35) mg/L, above adult reference values and Ctrough, 1.5(111) mg/L, like adult values. The nucleoside reverse-transcriptase inhibitor backbone was not found to affect darunavir concentrations. Simulated WHO-recommended darunavir/ritonavir doses showed exposures equivalent to adults. Higher alpha-1-acid glycoprotein increased binding to darunavir and decreased apparent clearance of darunavir. Conclusions: Darunavir exposures achieved in our trial are within safe range. Darunavir/ritonavir can safely be co-administered with TAF/FTC. Both WHO-recommended 600/100 mg and CHAPAS-4 800/100 mg darunavir/ritonavir doses for the 25-34.9 kg weight band offer favourable exposures. The choice between them can depend on tablet availability.
Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial

Nicholas I Paton,Meera Gurumurthy,Qingshu Lu,Francesca Leek,Philip Kwan,Hiromi W L Koh,James Molton,Lalaine Mortera,Sullian Naval,Zamzurina Abu Bakar,Yong-Kek Pang,Lionel Lum,Tow Keang Lim,Gail B Cross,Ganesh Lekurwale,Hyungwon Choi,Veonice Au,John Connolly,Martin Hibberd,Justin A Green,Meera Gurumurthy,James Molton,Claire Naftalin,Benjamin Yeo,Padmasayee Papineni,Gail Cross,Philip Kwan,Nicholas Paton,Kristina Rutkute,Ling Jun,Yan Pang,Hyungwon Choi,Hiromi Wai Ling Koh,David Townsend,John Totman,Francesca Leek,Benjamin Thomas,Tow Keang Lim,Lionel Lum,James Molton,Gail Cross,Claire Naftalin,Yan Pang,Nicholas Paton,Grace Xie,Xie Qi,Bu Duo Yu,Yuchen Lin,Yin Shan Lim,Siang Nee Teoh,Roland Jureen,Donald Chia,Cindy Chiu,Khor Lih Kin,James Hallinan,Felicia Tee,Eng Chon Boon,Qingshu Lu,Siok Ting Ng,Timothy Quek,Siew Hoon Tan,Koh Sze Kee,Sandra Hsing,Tan Choon Ping,Lau Suelyn,Jane Yeo,Ho Shuet Han,Ganesh Lekurwale,Su Jie,Yogesh Pokharkar,Rajesh Moorakonda,Martin Hibberd,Paola deSessions,Bala Periaswamy,Collins Chu,John Connolly,Veonice Au,Gerald Chua,Lin Lin,Wan Hian,Augustine Tee,Samuel Hong,Dato Abdul Razak,Zamzurina Abu Bakar,Yong-Kek Pang,Nur Azwin,Amirah Mohamed Tahir,Abdul Jalil,Lalaine Mortera,Megan Tadeo,Frances Tadeo,Fria Los Santos,Alden Bulicatin,Zyra Del Rosario,Anthony Geronimo,Mark Bernardino,Glaiza Erika Guda,Yong Wei Peng,Lim Seng Gee,Tan Tiong Har,Jenny Low,Justin Green,Susan Dixon,Nathanael Springman,Vicki Rousell,Thomas Lee,Bonnie Orr,Keguan Chen,Stephen DeWall,Alison Webster,Nick Cammack,Pascolizumab Tuberculosis Trial Team

DOI: https://doi.org/10.1093/infdis/jiae104

2024-04-09

The Journal of Infectious Diseases

Abstract:Background Interleukin 4 (IL-4), increased in tuberculosis infection, may impair bacterial killing. Blocking IL-4 confers benefit in animal models. We evaluated safety and efficacy of pascolizumab (humanized anti–IL-4 monoclonal antibody) as adjunctive tuberculosis treatment. Methods Participants with rifampicin-susceptible pulmonary tuberculosis received a single intravenous infusion of pascolizumab or placebo, and standard 6-month tuberculosis treatment. Pascolizumab dose increased in successive cohorts: (1) nonrandomized 0.05 mg/kg (n = 4); (2) nonrandomized 0.5 mg/kg (n = 4); (3) randomized 2.5 mg/kg (n = 9) or placebo (n = 3); and (4) randomized 10 mg/kg (n = 9) or placebo (n = 3). Coprimary safety outcome was study-drug–related grade 4 or serious adverse event (G4/SAE) in all cohorts (1–4). Coprimary efficacy outcome was week 8 sputum culture time-to-positivity (TTP) in randomized cohorts (3–4) combined. Results Pascolizumab levels exceeded IL-4 50% neutralizing dose for 8 weeks in 78%–100% of participants in cohorts 3–4. There were no study-drug–related G4/SAEs. Median week-8 TTP was 42 days in pascolizumab and placebo groups (P = .185). Rate of TTP increase was greater with pascolizumab (difference from placebo 0.011 log10 TTP/day; 95% Bayesian credible interval 0.006 to 0.015 log10 TTP/day). Conclusions There was no evidence to suggest blocking IL-4 was unsafe. Preliminary efficacy findings are consistent with animal models. This supports further investigation of adjunctive anti–IL-4 interventions for tuberculosis in larger phase 2 trials. Clinical Trials Registration NCT 01638520.

immunology,infectious diseases,microbiology
Exotic electronic properties in Thue–Morse graphene superlattices

Yafang Xu,Jianfei Zou,G. Jin

DOI: https://doi.org/10.1088/0953-8984/25/24/245301

2013-05-24

Abstract:To show the specific behavior of Dirac fermions in a quasi-periodic structure, we investigate the electronic properties in a deterministic Thue–Morse graphene superlattice. Our main findings include the following. (i) Unlike conventional Schrödinger electrons, quasi-periodic features such as the striking self-similarity and trifurcation in the transmission spectrum can be manifested only at oblique incidence. (ii) In the vicinity of the usual Dirac point, extra Dirac points emerge; their locations are dependent merely on the second generation of the Thue–Morse structure and the number is double that in the periodic graphene superlattice. (iii) A classification is given about the wavefunctions in the Thue–Morse structure which are transformed from the critical states into extended ones at the Dirac points. (iv) The electrons can transmit perfectly at the extra Dirac points, and such a collimation supplies a convenient way to experimentally detect the numbers and the locations of the extra Dirac points. These exotic electronic properties in the aperiodic graphene superlattices may facilitate some applications in graphene-based electronics.
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Bern-Thomas Nyang'wa,Catherine Berry,Emil Kazounis,Ilaria Motta,Nargiza Parpieva,Zinaida Tigay,Ronelle Moodliar,Matthew Dodd,Varvara Solodovnikova,Irina Liverko,Shakira Rajaram,Mohammed Rassool,Timothy McHugh,Melvin Spigelman,David A Moore,Koert Ritmeijer,Philipp du Cros,Katherine Fielding,TB-PRACTECAL team,Erin Da Costa,Nathalie Lachenal,Nicola James,Animesh Sinha,Kristen LeBeau,Emma Douch,Pascal Jolivert,Hannah Poulsom,Marion Conijn,Sean King,Hannah Spencer,Emma Cunden,Charlotte Batts,Thuy Vuong,Sebastian Dietrich,Melissa McRae,Sidney Wong,Eugene Sun,Morounfolu Olugbosi,Leslie Shanks,Michael Hughes,Payam Nahid,Johnstone Kumwenda,Todd Lorenz,Suman Majumdar,Robert C Horsburgh,Eric Nuermberger,Graeme Meintjes,Kathleen Eisenach,Christian Lienhardt,Andrew Nunn,Christoph Lange,Laura Park,Charlotte Gatts,Dominic Warren,Robert Kleiman,George Mokua Nyangweso,Michael Ochieng,Thaddaeus Egondi,Kevin Onyango,Truphoso Omollo,Raymond Omollo,Jo Sturgess,Steven Saunders,Elizabeth Allen,Suzanne Gajewski,Valentina Butoescu,Jarmila Hanekova,Coralie Etter,Yerkbulan Kambarov,Siza Mphele,Victoria Sukhinina,Olesya Huzar,Andrey Reshetnikov,Christine Cilliè,Nada Ahmed,Robert Hunt,Corinne Merle,Allanazarova Gulayim,Mansa Mbenga,Zlikha Saparbaevna Baltasheva,Tleubergen Abdrasuliev,Hasmik Margaryan,Utemuratova Gozzal Urgenishbaevna,Alena Skrahina,Natalia Yatskevich,Dzmitry Viatushka,Tatsiana Apanasevich,Aliaksandr Skrahin,Lynette Duckworth,Cindy Narasimooloo,Ndlovu Ellah Lesego,Sharon Motlhako,Mamomoko Ephenia Mashamaite,Evelyn Mojapelo

DOI: https://doi.org/10.1016/S2213-2600(23)00389-2

Abstract:Background: Around 500 000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are needed. Following an interim analysis, we report the final safety and efficacy outcomes of the TB-PRACTECAL trial, evaluating the safety and efficacy of oral regimens for the treatment of rifampicin-resistant tuberculosis. Methods: This open-label, randomised, controlled, multi-arm, multicentre, non-inferiority trial was conducted at seven hospital and community sites in Uzbekistan, Belarus, and South Africa, and enrolled participants aged 15 years and older with pulmonary rifampicin-resistant tuberculosis. Participants were randomly assigned, in a 1:1:1:1 ratio using variable block randomisation and stratified by trial site, to receive 36-80 week standard care; 24-week oral bedaquiline, pretomanid, and linezolid (BPaL); BPaL plus clofazimine (BPaLC); or BPaL plus moxifloxacin (BPaLM) in stage one of the trial, and in a 1:1 ratio to receive standard care or BPaLM in stage two of the trial, the results of which are described here. Laboratory staff and trial sponsors were masked to group assignment and outcomes were assessed by unmasked investigators. The primary outcome was the percentage of participants with a composite unfavourable outcome (treatment failure, death, treatment discontinuation, disease recurrence, or loss to follow-up) at 72 weeks after randomisation in the modified intention-to-treat population (all participants with rifampicin-resistant disease who received at least one dose of study medication) and the per-protocol population (a subset of the modified intention-to-treat population excluding participants who did not complete a protocol-adherent course of treatment (other than because of treatment failure or death) and those who discontinued treatment early because they violated at least one of the inclusion or exclusion criteria). Safety was measured in the safety population. The non-inferiority margin was 12%. This trial is registered with ClinicalTrials.gov, NCT02589782, and is complete. Findings: Between Jan 16, 2017, and March 18, 2021, 680 patients were screened for eligibility, of whom 552 were enrolled and randomly assigned (152 to the standard care group, 151 to the BPaLM group, 126 to the BPaLC group, and 123 to the BPaL group). The standard care and BPaLM groups proceeded to stage two and are reported here, post-hoc analyses of the BPaLC and BPaL groups are also reported. 151 participants in the BPaLM group and 151 in the standard care group were included in the safety population, with 138 in the BPaLM group and 137 in the standard care group in the modified intention-to-treat population. In the modified intention-to-treat population, unfavourable outcomes were reported in 16 (12%) of 137 participants for whom outcome was assessable in the BPaLM group and 56 (41%) of 137 participants in the standard care group (risk difference -29·2 percentage points [96·6% CI -39·8 to -18·6]; non-inferiority and superiority p<0·0001). 34 (23%) of 151 participants receiving BPaLM had adverse events of grade 3 or higher or serious adverse events, compared with 72 (48%) of 151 participants receiving standard care (risk difference -25·2 percentage points [96·6% CI -36·4 to -13·9]). Five deaths were reported in the standard care group by week 72, of which one (COVID-19 pneumonia) was unrelated to treatment and four (acute pancreatitis, suicide, sudden death, and sudden cardiac death) were judged to be treatment-related. Interpretation: The 24-week, all-oral BPaLM regimen is safe and efficacious for the treatment of pulmonary rifampicin-resistant tuberculosis, and was added to the WHO guidance for treatment of this condition in 2022. These findings will be key to BPaLM becoming the preferred regimen for adolescents and adults with pulmonary rifampicin-resistant tuberculosis. Funding: Médecins Sans Frontières.
Factors associated with the acceptability of Lopinavir/Ritonavir formulations among children living with HIV/AIDS attending care and treatment clinics in Mbeya and Mwanza, Tanzania

Nadiya Alnoor Jiwa,Eunice Ketang’enyi,Kapongola Nganyanyuka,Ruth Mbwanji,Danistan Mwenisongole,Eutropia Masuka,Mary Brown,Mary Charles,Davance Leonard Mwasomola,Thomas Nyangalima,Willyhelmina Olomi,Lilian Komba,Judith Gwimile,Bertha Kasambala,Lumumba Mwita

DOI: https://doi.org/10.1371/journal.pone.0292424

IF: 3.7

2024-01-02

PLoS ONE

Abstract:Introduction Children living with chronic illnesses are offered formulations based on manufacturer and distributor research. The aim of this study is to better understand the perspectives of children and their caregivers in accepting Lopinavir/ritonavir (LPV/r) formulations. Methods 362 participants were recruited from two pediatric HIV/AIDS clinics in Mbeya and Mwanza, Tanzania, from December 2021 to May 2022. A translated questionnaire was piloted and validated at both clinics, followed by the implementation of a cross-sectional study. Results 169 participants (47.1%) reported general difficulties in swallowing, regardless of formulation, while 34.3% and 38.5% reported vomiting tablets and syrups, respectively. Statistical significance is shown to support that children can swallow medications if they can eat stiffened porridge ( Ugali ). This correlated with the lower incidence of younger children being able to swallow compared to older children (above six years of age). Children older than six years preferred taking tablets (independent of daily dosage) better than other formulations. Significantly, older children who attend school were associated with high odds of swallowing medicine (AOR = 3.06, 95%CI; 1.32–7.05); however, age was not found to be statistically related to ease of administration for Lopinavir/Ritonavir in this study. Conclusions Lopinavir/Ritonavir tablets remain the most accepted formulation among children and adolescents with HIV/AIDS. This study highlights the impact of various factors affecting the acceptability of pediatric formulation, suggesting that children younger than six years, unable to eat Ugali and not attending schools may be most vulnerable regarding their ability to accept Lopinavir/Ritonavir formulations. Further studies are needed to assess the acceptability of other medications in chronically ill children.

multidisciplinary sciences
Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial

Fred C Semitala,Jillian L Kadota,Allan Musinguzi,Fred Welishe,Anne Nakitende,Lydia Akello,Lynn Kunihira Tinka,Jane Nakimuli,Joan Ritar Kasidi,Opira Bishop,Suzan Nakasendwa,Yeonsoo Baik,Devika Patel,Amanda Sammann,Payam Nahid,Robert Belknap,Moses R Kamya,Margaret A Handley,Patrick Pj Phillips,Anne Katahoire,Christopher A Berger,Noah Kiwanuka,Achilles Katamba,David W Dowdy,Adithya Cattamanchi,Fred C. Semitala,Jillian L. Kadota,Moses R. Kamya,Margaret A. Handley,Patrick PJ Phillips,Christopher A. Berger,David W. Dowdy

DOI: https://doi.org/10.1371/journal.pmed.1004356

2024-02-22

PLoS Medicine

Abstract:Expanding access to shorter regimens for tuberculosis (TB) prevention, such as once-weekly isoniazid and rifapentine taken for 3 months (3HP), is critical for reducing global TB burden among people living with HIV (PLHIV). Our coprimary hypotheses were that high levels of acceptance and completion of 3HP could be achieved with delivery strategies optimized to overcome well-contextualized barriers and that 3HP acceptance and completion would be highest when PLHIV were provided an informed choice between delivery strategies. In a pragmatic, single-center, 3-arm, parallel-group randomized trial, PLHIV receiving care at a large urban HIV clinic in Kampala, Uganda, were randomly assigned (1:1:1) to receive 3HP by facilitated directly observed therapy (DOT), facilitated self-administered therapy (SAT), or informed choice between facilitated DOT and facilitated SAT using a shared decision-making aid. We assessed the primary outcome of acceptance and completion (≥11 of 12 doses of 3HP) within 16 weeks of treatment initiation using proportions with exact binomial confidence intervals (CIs). We compared proportions between arms using Fisher's exact test (two-sided α = 0.025). Trial investigators were blinded to primary and secondary outcomes by study arm. Between July 13, 2020, and July 8, 2022, 1,656 PLHIV underwent randomization, with equal numbers allocated to each study arm. One participant was erroneously enrolled a second time and was excluded in the primary intention-to-treat analysis. Among the remaining 1,655 participants, the proportion who accepted and completed 3HP exceeded the prespecified 80% target in the DOT (0.94; 97.5% CI [0.91, 0.96] p < 0.001), SAT (0.92; 97.5% CI [0.89, 0.94] p < 0.001), and Choice (0.93; 97.5% CI [0.91, 0.96] p < 0.001) arms. There was no difference in acceptance and completion between any 2 arms overall or in prespecified subgroup analyses based on sex, age, time on antiretroviral therapy, and history of prior treatment for TB or TB infection. Only 14 (0.8%) participants experienced an adverse event prompting discontinuation of 3HP. The main limitation of the study is that it was conducted in a single center. Multicenter studies are now needed to confirm the feasibility and generalizability of the facilitated 3HP delivery strategies in other settings. Short-course TB preventive treatment was widely accepted by PLHIV in Uganda, and very high levels of treatment completion were achieved in a programmatic setting with delivery strategies tailored to address known barriers. ClinicalTrials.gov NCT03934931.

medicine, general & internal
Remarks by Louis W. Sullivan, MD, Secretary of Health and Human Services, at the sixth annual meeting of the Association for Academic Minority Physicians, October 23-25, 1992, Washington, DC.

L. Sullivan

Abstract:
Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease

Connie A Haley,Marcos C Schechter,David Ashkin,Charles A Peloquin,J Peter Cegielski,Barbara B Andrino,Marcos Burgos,Lori A Caloia,Lisa Chen,Angel Colon-Semidey,Malini B DeSilva,Shireesha Dhanireddy,Susan E Dorman,Felicia F Dworkin,Heidi Hammond-Epstein,Alice V Easton,James T Gaensbauer,Bijan Ghassemieh,Maria E Gomez,David Horne,Supriya Jasuja,Betsy A Jones,Leonard J Kaplan,Asharaf Edward Khan,Elizabeth Kracen,Sarah Labuda,Karen M Landers,Alfred A Lardizabal,Maria T Lasley,David M Letzer,Vinicius K Lopes,Ronald J Lubelchek,C Patricia Macias,Aimee Mihalyov,Elizabeth Ann Misch,Jason A Murray,Masahiro Narita,Diana M Nilsen,Megan J Ninneman,Lynne Ogawa,Alawode Oladele,Melissa Overman,Susan M Ray,Kathleen A Ritger,Marie-Claire Rowlinson,Nadya Sabuwala,Thomas M Schiller,Lawrence E Schwartz,Christopher Spitters,Douglas B Thomson,Rene Rico Tresgallo,Patrick Valois,Neela D Goswami,BPaL Implementation Group,Rocio Agraz-Lara,Amina Ahmed,Ana Alvarez,Lisa Armitage,Pennan Barry,Robert Belknap,John Bernardo,Mary Bravo,Sarah Brode,Elizabeth Burden,Joseph Burzynski,Caralee Caplan-Shaw,Ken Castro,Terry Chorba,William Connors,Victoria Cook,Andrea Cruz,Charles Daley,Shom Dasgupta,Sonia Dhingra,Thomas Dobbs,Ellen Elmore,Frank Erwin,Vincent Escuyer,Christina Fiske,Beth Gadkowski,German Henestroza,Julie Higashi,Shereen Katrak,Chris Keh,Amanda Khalil,Lilian Kigonya,Michael Lauzardo,Sapna Morris,Sonal Munsiff,Scott Nabity,Margaret Oxtoby,Amee Patrawalla,Allison Phillips,Ann Raftery,Caitlin Reed,Brian Rock,Kelly Russo,Harleen Sahini,Paul Saleeb,Roberto Santos,Barbara Seaworth,Joanna Shaw-KaiKai,Jeff Starke,Jason Stout,Wesley Stubblefield,Zelalem Temesgen,Keziah Thomas,Jeffrey Tornheim,Caryn Upton,Daniel Urbine,Shu-Hua Wang,Jon Warkentin,Risa Webb,John Wilson,Johnathan Wortham,And Salinia Yu,Claudia Altman,Irfan Hafiz,Deepa Prabhakar,William Bowler

DOI: https://doi.org/10.1093/cid/ciad312

2023-10-05

Abstract:Background: Rifampin-resistant tuberculosis is a leading cause of morbidity worldwide; only one-third of persons start treatment, and outcomes are often inadequate. Several trials demonstrate 90% efficacy using an all-oral, 6-month regimen of bedaquiline, pretomanid, and linezolid (BPaL), but significant toxicity occurred using 1200-mg linezolid. After US Food and Drug Administration approval in 2019, some US clinicians rapidly implemented BPaL using an initial 600-mg linezolid dose adjusted by serum drug concentrations and clinical monitoring. Methods: Data from US patients treated with BPaL between 14 October 2019 and 30 April 2022 were compiled and analyzed by the BPaL Implementation Group (BIG), including baseline examination and laboratory, electrocardiographic, and clinical monitoring throughout treatment and follow-up. Linezolid dosing and clinical management was provider driven, and most patients had linezolid adjusted by therapeutic drug monitoring. Results: Of 70 patients starting BPaL, 2 changed to rifampin-based therapy, 68 (97.1%) completed BPaL, and 2 of the 68 (2.9%) experienced relapse after completion. Using an initial 600-mg linezolid dose daily adjusted by therapeutic drug monitoring and careful clinical and laboratory monitoring for adverse effects, supportive care, and expert consultation throughout BPaL treatment, 3 patients (4.4%) with hematologic toxicity and 4 (5.9%) with neurotoxicity required a change in linezolid dose or frequency. The median BPaL duration was 6 months. Conclusions: BPaL has transformed treatment for rifampin-resistant or intolerant tuberculosis. In this cohort, effective treatment required less than half the duration recommended in 2019 US guidelines for drug-resistant tuberculosis. Use of individualized linezolid dosing and monitoring likely enhanced safety and treatment completion. The BIG cohort demonstrates that early implementation of new tuberculosis treatments in the United States is feasible.
Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis

Fajri Gafar,Roeland E Wasmann,Helen M McIlleron,Rob E Aarnoutse,H Simon Schaaf,Ben J Marais,Dipti Agarwal,Sampson Antwi,Nguyen D Bang,Adrie Bekker,David J Bell,Chishala Chabala,Louise Choo,Geraint R Davies,Jeremy N Day,Rajeshwar Dayal,Paolo Denti,Peter R Donald,Ephrem Engidawork,Anthony J Garcia-Prats,Diana Gibb,Stephen M Graham,Anneke C Hesseling,Scott K Heysell,Misgana I Idris,Sushil K Kabra,Aarti Kinikar,Agibothu K Hemanth Kumar,Awewura Kwara,Rakesh Lodha,Cecile Magis-Escurra,Nilza Martinez,Binu S Mathew,Vidya Mave,Estomih Mduma,Rachel Mlotha-Mitole,Stellah G Mpagama,Aparna Mukherjee,Heda M Nataprawira,Charles A Peloquin,Thomas Pouplin,Geetha Ramachandran,Jaya Ranjalkar,Vandana Roy,Rovina Ruslami,Ira Shah,Yatish Singh,Marieke G G Sturkenboom,Elin M Svensson,Soumya Swaminathan,Urmila Thatte,Stephanie Thee,Tania A Thomas,Tjokosela Tikiso,Daan J Touw,Anna Turkova,Thirumurthy Velpandian,Lilly M Verhagen,Jana L Winckler,Hongmei Yang,Vycke Yunivita,Katja Taxis,Jasper Stevens,Jan-Willem C Alffenaar,Global Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in Pharmacokinetics of Anti-TB Drugs

DOI: https://doi.org/10.1183/13993003.01596-2022

2023-03-09

Abstract:Background: Suboptimal exposure to antituberculosis (anti-TB) drugs has been associated with unfavourable treatment outcomes. We aimed to investigate estimates and determinants of first-line anti-TB drug pharmacokinetics in children and adolescents at a global level. Methods: We systematically searched MEDLINE, Embase and Web of Science (1990-2021) for pharmacokinetic studies of first-line anti-TB drugs in children and adolescents. Individual patient data were obtained from authors of eligible studies. Summary estimates of total/extrapolated area under the plasma concentration-time curve from 0 to 24 h post-dose (AUC0-24) and peak plasma concentration (C max) were assessed with random-effects models, normalised with current World Health Organization-recommended paediatric doses. Determinants of AUC0-24 and C max were assessed with linear mixed-effects models. Results: Of 55 eligible studies, individual patient data were available for 39 (71%), including 1628 participants from 12 countries. Geometric means of steady-state AUC0-24 were summarised for isoniazid (18.7 (95% CI 15.5-22.6) h·mg·L-1), rifampicin (34.4 (95% CI 29.4-40.3) h·mg·L-1), pyrazinamide (375.0 (95% CI 339.9-413.7) h·mg·L-1) and ethambutol (8.0 (95% CI 6.4-10.0) h·mg·L-1). Our multivariate models indicated that younger age (especially <2 years) and HIV-positive status were associated with lower AUC0-24 for all first-line anti-TB drugs, while severe malnutrition was associated with lower AUC0-24 for isoniazid and pyrazinamide. N-acetyltransferase 2 rapid acetylators had lower isoniazid AUC0-24 and slow acetylators had higher isoniazid AUC0-24 than intermediate acetylators. Determinants of C max were generally similar to those for AUC0-24. Conclusions: This study provides the most comprehensive estimates of plasma exposures to first-line anti-TB drugs in children and adolescents. Key determinants of drug exposures were identified. These may be relevant for population-specific dose adjustment or individualised therapeutic drug monitoring.
Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis

Huy X Ngo,Ava Y Xu,Gustavo E Velásquez,Nan Zhang,Vincent K Chang,Ekaterina V Kurbatova,William C Whitworth,Erin Sizemore,Kia Bryant,Wendy Carr,Marc Weiner,Kelly E Dooley,Melissa Engle,Susan E Dorman,Payam Nahid,Susan Swindells,Richard E Chaisson,Pheona Nsubuga,Madeleine Lourens,Rodney Dawson,Radojka M Savic

DOI: https://doi.org/10.1093/cid/ciae119

IF: 20.999

2024-03-12

Clinical Infectious Diseases

Abstract:Background The optimal dosing strategy for rifampicin in treating drug-susceptible tuberculosis (TB) is still highly debated. In the Phase 3 clinical trial Study 31/ACTG 5349 (NCT02410772), all participants in the control regimen arm received 600 mg rifampicin daily as a flat dose. Here, we evaluated relationships between rifampicin exposure and efficacy and safety outcomes. Methods We analyzed rifampicin concentration time profiles using population nonlinear mixed-effects models. We compared simulated rifampicin exposure from flat- and weight-banded dosing. We evaluated the effect of rifampicin exposure on stable culture conversion at 6 months, TB-related unfavorable outcomes at 9, 12, and 18 months using Cox proportional hazard models, and all trial-defined safety outcomes using logistic regression. Results Our model derived rifampicin exposure ranged from 4.57 mg·h/L to 140.0 mg·h/L with a median of 41.8 mg·h/L. Pharmacokinetic simulations demonstrated that flat-dosed rifampicin provided exposure coverage similar to weight-banded dose. Exposure-efficacy analysis (N=680) showed that participants with rifampicin exposure below the median experienced similar hazards of stable culture conversion and TB-related unfavorable outcomes compared to those with exposure above the median. Exposure-safety analysis (N=722) showed that increased rifampicin exposure was not associated with increased grade 3 or higher adverse events, or serious adverse events. Conclusions Flat-dosing of rifampicin at 600 mg daily may be a reasonable alternative to the incumbent weight-banded dosing strategy for the standard of care 6-month regimen. Future research should assess the optimal dosing strategy for rifampicin, at doses higher than the current recommendation.

immunology,infectious diseases,microbiology
Treatment of diverticulitis; medical management & surgical management.

E. G. Wakefield,R. Turnbull

DOI: https://doi.org/10.1080/00325481.1958.11692120

1958-06-01

Postgraduate Medicine

Abstract:
Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study

Oleksandr Korotych,Jay Achar,Elmira Gurbanova,Arax Hovhannesyan,Nino Lomtadze,Ana Ciobanu,Alena Skrahina,Gunta Dravniece,Liga Kuksa,Michael Rich,Naira Khachatryan,Myroslava Germanovych,Abdullat Kadyrov,Iana Terleieva,Irada Akhundova,Malik Adenov,Myahri Durdyeva,Nana Kiria,Nargiza Parpieva,Natalia Yatskevich,Rovshen Jumayev,Rustam Nurov,Saulius Diktanas,Valentina Vilc,Giovanni Battista Migliori,Askar Yedilbayev

DOI: https://doi.org/10.1016/S1473-3099(24)00228-7

Abstract:Background: In 2020, WHO guidelines prioritised the use of a standard fully oral short treatment regimen (STR) consisting of bedaquiline, levofloxacin or moxifloxacin, ethionamide, ethambutol, high-dose isoniazid, pyrazinamide, and clofazimine for the management of rifampicin-resistant tuberculosis. A high prevalence of resistance to constituent drugs precluded its widespread use by countries in the WHO European region. We evaluated three 9-month fully oral modified STRs (mSTRs) in which ethionamide, ethambutol, isoniazid, and pyrazinamide were replaced by linezolid, cycloserine, or delamanid (or a combination). Methods: This multicountry, prospective, single-arm, cohort study examined the effectiveness and safety of mSTRs for fluoroquinolone-susceptible, rifampicin-resistant pulmonary tuberculosis in 13 countries in the WHO European region during 2020-23. We enrolled adults and children of all ages with bacteriologically confirmed rifampicin-resistant, fluoroquinolone-susceptible pulmonary tuberculosis, and children (aged 0-18 years) with clinically diagnosed disease and a confirmed contact with rifampicin-resistant, fluoroquinolone-susceptible tuberculosis. Participants aged 6 years or older received one of two regimens: bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine; or bedaquiline, linezolid, levofloxacin, clofazimine, and delamanid. Children younger than 6 years received delamanid, linezolid, levofloxacin, and clofazimine. Participants were followed up for 12 months after successful treatment completion to detect recurrence and death. The primary outcome was the cumulative probability of not having an unsuccessful study outcome (defined as treatment failure, on-treatment loss to follow-up, death, or recurrence) before 22 months of study follow-up. The primary safety outcome was the incidence of each adverse event of interest (peripheral neuropathy, optic neuritis, myelosuppression, hepatitis, prolonged QT interval, hypokalaemia, and acute kidney injury) of grade 3 or higher severity during the treatment course. Findings: Between Aug 28, 2020 and May 26, 2021, 7272 patients were screened and 2636 were included in the treatment cohort. 1966 (74·6%) were male, 670 (25·4%) were female, and median age was 43 years (IQR 33-53). Treatment success was recorded for 2181 (82·7%) participants. The cumulative probability of not having an unsuccessful study outcome 22 months after treatment initiation was 79% (95% CI 78-81). Increasing age (adjusted hazard ratio 2·61 [95% CI 1·70-4·04] for people aged >64 years vs 35-44 years), HIV-positive status (1·53 [1·16-2·01]), presence of bilateral cavities (1·68 [1·29-2·19]), smoking history (1·34 [1·05-1·71]), baseline anaemia (1·46 [1·15-1·86]), unemployment (1·37 [1·04-1·80]), elevated baseline liver enzymes (1·40 [1·13-1·73]), and excessive alcohol use (1·47 [1·14-1·89]) were positively associated with unsuccessful study outcomes. In the safety cohort of 2813 participants who received at least one dose, 301 adverse events of interest were recorded in 252 (9·0%) participants with the most frequent being myelosuppression (139 [4·9%] participants, 157 [52·2%] events). Interpretation: The high treatment success and good safety results indicate considerable potential for the use of mSTRs in programmatic conditions, especially for individuals not eligible for the current WHO-recommended 6-month regimen and in settings with a need for alternative options. Funding: The Global Fund to Fight AIDS, Tuberculosis and Malaria; United States Agency for International Development; Government of Germany; and WHO. Translation: For the Russian translation of the abstract see Supplementary Materials section.
Rational design of targeted cancer therapeutics through the multiconjugation of folate and cleavable siRNA to RAFT-synthesized (HPMA-s-APMA) copolymers.

Adam W. York,Faqing Huang,C. McCormick

DOI: https://doi.org/10.1021/bm901249n

2010-02-08

Biomacromolecules

Abstract:A well-defined N-(2-hydroxypropyl)methacrylamide-s-N-(3-aminopropyl)methacrylamide (HPMA-s-APMA) copolymer, synthesized via reversible addition-fragmentation chain transfer (RAFT) polymerization, was utilized for the rational design of multiconjugates containing both a gene therapeutic, small interfering RNA (siRNA), and a cancer cell targeting moiety, folate. The copolymer contains a biocompatible poly(HPMA) portion (91 mol %) and a primary amine, APMA, portion (9 mol %). A fraction (20 mol %) of the APMA repeats were converted to activated thiols utilizing the amine- and sulfhydryl-reactive molecule N-succinimidyl 3-(2-pyridyldithio)-propionate (SPDP). 5'-Thiolated sense strand RNAs were then coupled to the polymer through a disulfide exchange with pendant pyridyldithio moieties, giving an 89 +/- 4% degree of conjugation. The unmodified APMA units (80 mol %) were subsequently coupled to amine reactive folates with 81 +/- 1% efficiency. This yielded a multiconjugate copolymer with 91 mol % HPMA, 2 mol % RNA, and 6 mol % folate. siRNA formation was achieved by annealing antisense strands to the conjugated RNA sense strands. Subsequent siRNA cleavage under intracellular conditions demonstrated the potential utility of this carrier in gene delivery. The multiconjugate copolymer and siRNA release were characterized by UV-vis spectroscopy and polyacrylamide gel electrophoresis.
From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.

M. Millan

DOI: https://doi.org/10.1016/j.pharmthera.2010.06.002

2010-11-01

Abstract:
Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study

Laura Olbrich,Zoe Franckling-Smith,Leyla Larsson,Issa Sabi,Nyanda Elias Ntinginya,Celso Khosa,Denise Banze,Marriott Nliwasa,Elizabeth Lucy Corbett,Robina Semphere,Valsan Philip Verghese,Joy Sarojini Michael,Marilyn Mary Ninan,Elmar Saathoff,Timothy Daniel McHugh,Alia Razid,Stephen Michael Graham,Rinn Song,Pamela Nabeta,Andre Trollip,Mark Patrick Nicol,Michael Hoelscher,Christof Geldmacher,Norbert Heinrich,Heather Joy Zar,RaPaed-AIDA-TB consortium,Craig Dalgarno,Bariki Mtafya,Harieth Mwambola,Chiristina Manyama,Lwitiho Edwin Sudi,Emanuel Sichone,Daniel Mapamba,Willyhelmina Olomi,Peter Edwin,Anila Chacko,Ramya Kumari,Dhanabhagyam Naveena Krishnan,Nithya Munisamy,Deepa Mani,Cremildo Gomes Maueia,Carla Maria Madeira,Diana Kachere,Tamenji Chinoko,Tionge Daston Sikwese,Alice Mnyanga,Lingstone Chiume,Anna Mantsoki,Cynthia Biddle Baard,Jacinta Diane Munro,Margaretha Prins,Nolufefe Benzi,Linda Claire Bateman,Ashleigh Ryan,Kutala Booi,Nezisa Paulo,Anthenette Heydenrych,Wonita Petersen,Raquel Brookes,Michele Mento,Chad Centner

DOI: https://doi.org/10.1016/S1473-3099(24)00494-8

2024-09-20

Abstract:Background: Despite causing high mortality worldwide, paediatric tuberculosis is often undiagnosed. We aimed to investigate optimal testing strategies for microbiological confirmation of tuberculosis in children younger than 15 years, including the yield in high-risk subgroups (eg, children younger than 5 years, with HIV, or with severe acute malnutrition [SAM]). Methods: For this secondary analysis, we used data from RaPaed-TB, a multicentre diagnostic accuracy study evaluating novel diagnostic assays and testing approaches for tuberculosis in children recruited from five health-care centres in Malawi, Mozambique, South Africa, Tanzania, and India conducted between Jan 21, 2019, and June 30, 2021. Children were included if they were younger than 15 years and had signs or symptoms of pulmonary or extrapulmonary tuberculosis; they were excluded if they weighed less than 2 kg, had received three or more doses of anti-tuberculosis medication at time of enrolment, were in a condition deemed critical by the local investigator, or if they did not have at least one valid microbiological result. We collected tuberculosis-reference specimens via spontaneous sputum, induced sputum, gastric aspirate, and nasopharyngeal aspirates. Microbiological tests were Xpert MTB/RIF Ultra (hereafter referred to as Ultra), liquid culture, and Löwenstein-Jensen solid culture, which were followed by confirmatory testing for positive cultures. The main outcome of this secondary analysis was categorising children as having confirmed tuberculosis if culture or Ultra positive on any sample, unconfirmed tuberculosis if clinically diagnosed, and unlikely tuberculosis if neither of these applied. Findings: Of 5313 children screened, 975 were enrolled, of whom 965 (99%) had at least one valid microbiological result. 444 (46%) of 965 had unlikely tuberculosis, 282 (29%) had unconfirmed tuberculosis, and 239 (25%) had confirmed tuberculosis. Median age was 5·0 years (IQR 1·8-9·0); 467 (48%) of 965 children were female and 498 (52%) were male. 155 (16%) of 965 children had HIV and 110 (11%) children had SAM. 196 (82%) of 239 children with microbiological detection tested positive on Ultra. 110 (46%) of 239 were confirmed by both Ultra and culture, 86 (36%) by Ultra alone, and 43 (18%) by culture alone. 'Trace' was the most common semiquantitative result (93 [40%] of 234). 481 (50%) of 965 children had only one specimen type collected, 99 (21%) of whom had M tuberculosis detected. 484 (50%) of 965 children had multiple specimens collected, 141 (29%) of whom were positive on at least one specimen type. Of the 102 children younger than 5 years with M tuberculosis detected, 80 (78%) tested positive on sputum. 64 (80%) of 80 children who tested positive on sputum were positive on sputum alone; 61 (95%) of 64 were positive on induced sputum, two (3%) of 64 were positive on spontaneous sputum, and one (2%) was positive on both. Interpretation: High rates of microbiological confirmation of tuberculosis in children can be achieved via parallel sampling and concurrent testing procedures. Sample types and choice of test to be used sequentially should be considered when applying to groups such as children younger than 5 years, living with HIV, or with SAM. Funding: European and Developing Countries Clinical Trials Partnership programme, supported by the EU, the UK Medical Research Council, Swedish International Development Cooperation Agency, Bundesministerium für Bildung und Forschung, the German Center for Infection Research, and Beckman Coulter.

Primary T-cell lymphoma of muscle in a patient infected with human immunodeficiency virus.

Clinical outcomes in children living with HIV treated for non-severe tuberculosis in the SHINE Trial

Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

Effectiveness of double-dose dolutegravir in people receiving rifampin-based tuberculosis treatment: an observational, cohort study of people with HIV from six countries

Treatment of schizophrenia and delusional disorder in the elderly

Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV

Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial

Exotic electronic properties in Thue–Morse graphene superlattices

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Factors associated with the acceptability of Lopinavir/Ritonavir formulations among children living with HIV/AIDS attending care and treatment clinics in Mbeya and Mwanza, Tanzania

Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial

Remarks by Louis W. Sullivan, MD, Secretary of Health and Human Services, at the sixth annual meeting of the Association for Academic Minority Physicians, October 23-25, 1992, Washington, DC.

Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease

Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis

Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis

Treatment of diverticulitis; medical management & surgical management.

Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study

Rational design of targeted cancer therapeutics through the multiconjugation of folate and cleavable siRNA to RAFT-synthesized (HPMA-s-APMA) copolymers.

From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.

Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study